Related Experiment Video
Updated: Jul 17, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Left ventricular hypertrophy regression: the LIVE trial
1Academic Cardiology Unit, Division of NHLI, Imperial College School of Medicine, St Mary's Hospital, Queen Elizabeth the Queen Mother Wing, London W2 1NY, UK.
Insights
The LIVE study found that indapamide effectively reduced left ventricular hypertrophy (LVH) in hypertensive patients over one year. This diuretic demonstrated efficacy comparable to enalapril in LVH regression.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Left ventricular hypertrophy (LVH) increases vascular event risk.
- Diuretic efficacy for LVH reduction is debated.
- Antihypertensive treatments are evaluated for LVH regression.
Purpose of the Study:
- To compare indapamide versus enalapril for LVH regression in hypertensive patients.
- To assess the efficacy of indapamide 1.5 mg daily and enalapril 20 mg daily.
- To evaluate LVH reduction after one year of treatment.
Main Methods:
- Prospective, double-blind, randomized controlled trial (LIVE study).
- Inclusion criteria: Hypertensive patients with LVH.
- Echocardiography used for LVH assessment, with blind reading by an independent committee.
Main Results:
- Preliminary data confirm indapamide's antihypertensive efficacy.
- Indapamide showed efficacy in reducing left ventricular mass.
- Progressive LVH reduction observed over one year with indapamide.
Conclusions:
- Indapamide is effective in reducing left ventricular hypertrophy in hypertensive patients.
- The study provides evidence for indapamide's role in managing LVH.
- Indapamide offers a viable treatment option for hypertensive patients with LVH.
Abstract:
Left ventricular hypertrophy (LVH) is a clinical condition associated with an increased risk of vascular events. Several trials have been done to evaluate the action of different antihypertensive treatments on the regression of LVH IN HYPERTENSIVE PATIENTS. The efficacy of diuretics in the reduction of LVH is controversial. The LIVE study (Left Ventricular Hypertrophy Regression: Indapamide Versus Enalapril) is a European, prospective, double-blind, randomised, controlled trial aimed to compare the efficacy of indapamide 1.5 mg daily with that of enalapril 20 mg daily in the reduction of LVH in hypertensive patients (systolic blood pressure > 160 and < 210 mmHg) with LVH (left ventricular mass index 120 g/m2 in men and > 100 g/m2 in women) after 1 year of treatment. The assessment of LVH was done by echocardiography. A blind randomised reading of the echo recordings was performed at the end of the study by an independent Core Echocardiography Committee with three readers. Preliminary data are available from this trial. These data confirm the antihypertensive efficacy of indapamide and its efficacy in the reduction of left ventricular mass through a progressive action over 1 year.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

